Patents Assigned to IPSOGEN
  • ASXL1 AS A NEW DIAGNOSTIC MARKER OF MYELOID NEOPLASMS
    Publication number: 20130059301
    Abstract: A method for diagnosing a myeloid cancer in a subject, includes the step of analyzing a biological sample from the subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID N°2. A kit for diagnosing myeloid cancer in a subject including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method is also described.
    Type: Application
    Filed: February 11, 2011
    Publication date: March 7, 2013
    Applicants: INSTITUT PAOLI-CALMETTES, IPSOGEN
    Inventors: Véronique Gelsi-Boyer, Daniel Birnbaum
  • METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS
    Publication number: 20110244459
    Abstract: Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library.
    Type: Application
    Filed: December 9, 2009
    Publication date: October 6, 2011
    Applicants: IPSOGEN, INSERM-INSTITUT NATIONAL DE LA SANTE ET DE LA rECHERCHE MEDICALE, INSTITUT PAOLI-CALMETTES
    Inventors: Francois Bertucci, Rebecca Tagett, Sabrina Carpentier
  • BREAST CANCER EXPRESSION PROFILING
    Publication number: 20110014191
    Abstract: The present invention relates to a method for analyzing cancer. e.g., breast cancer including detection of differential expression of at least one of the 16 genes encoding serine/threonine kinases listed in Table 1, or of the 16 genes, and to a polynucleotide library including at least one the 16 genes. This finds use in the development of novel applications, in particular in the development of prognosis or diagnostic of breast cancer or for monitoring the treatment of a patient with a breast cancer.
    Type: Application
    Filed: December 24, 2008
    Publication date: January 20, 2011
    Applicants: IPSOGEN, INSTITUT PAOLI-CALMETTES
    Inventors: Francois Bertucci, Daniel Birnbaum, Pascal Finetti
  • METHODS OF ASSESSING A PROPENSITY OF CLINICAL OUTCOME FOR A FEMALE MAMMAL SUFFERING FROM BREAST CANCER
    Publication number: 20100234292
    Abstract: The present invention relates to a method of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer in view of the expression of specific nucleic acid sequences in a biological sample.
    Type: Application
    Filed: April 16, 2008
    Publication date: September 16, 2010
    Applicants: IPSOGEN, INSERM - INSTITUT NATIONAL DE LA SANTE ET DE LA RE CHECHE MEDICALE, INSTITUT PAOLI-CALMETTES
    Inventors: Francois Bertucci, Daniel Birnbaum, Patrice Viens, Vincent Fert, Fabienne Hermitte, Stephane Debono, Stephane Deraco, Nathalie Borie, Fanny Piette
  • Identification of a JAK2 mutation in Polycythemia Vera
    Patent number: 7429456
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: September 30, 2008
    Assignee: IPSOGEN
    Inventors: William Vainchenker, Valeria Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall